Impact of Particle Flocculation on Dissolution and Implications on **Bioavailability of Injectable Suspensions**

William Smith^{1,2}, Jungeun Bae^{1,2}, Ying Zhang¹, Yan Wang², Bin Qin², Darby Kozak², Muhammad Ashraf¹, Xiaoming Xu¹

Research (CDER), U.S. Food and Drug Administration (FDA)

PURPOSE

Particle size distribution (PSD) is a critical quality attribute of suspension-based injectable products, impacting dose uniformity, physical stability, dissolution and bioavailability. During formulation development, polymeric excipients and wetting agents are often included to induce particle flocculation to impart shelf stability, by controlling particle-particle interactions. The process of flocculation inherently changes PSD and may also cause unintended changes in drug release rate leading to variation in clinical performance. Using triamcinolone acetonide (TA) injectable suspensions as a model system, we intend to understand the relationships among particle flocculation, PSD and drug dissolution.




Figure 1. Polarize light micrograph (20x) of a representative TA injectable suspension sample.

METHODS

The PSD of three different commercial TA injectable suspensions were measured by laser diffraction (LD) (Malvern Mastersizer 3000) and compared. Impact of various measurement conditions (e.g., stir rate, sonication power, dispersion media, etc.) on the accuracy and precision of LD measurements were examined. Particle-free water or drug saturated solutions were used as dispersants. A non-sink in vitro drug release test (IVRT) method was developed to investigate the impact of shear on drug dissolution rates, by varying the introduction procedure: via 25-gauge syringe to simulate high shear and a micropipette to simulate low shear. In addition, a novel tandem LD-IVRT system was devised to simultaneously determine PSD and dissolution rate (Figure 1). [1]





Figure 2. View of internal flow path between laser diffraction flow cell and dispersion unit with an in situ fiber optic UV (IFO-UV) probe, for simultaneous dissolution and particle size determination.

1. Division of Product Quality Research, Office of Testing and Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and

2. Division of Therapeutic Performance I, Office of Research and Standards, Office of Generic Drugs, CDER, U.S. FDA

- during stirring (1000 s⁻¹).
- from large secondary particles approximately 60%.
- *method.*









Impact of Flocculation State on Particle Size Distribution and Dissolution




Figure 3.

A) Schematic of particle flocculates undergoing shear induced dissociation during injection.

B) Difference in particle size distribution caused by shear from differing introduction method (syringe vs. micropipette)

C) Difference in dissolution rate based on shear induced change in PSD.

6 Probing the Mechanism of Dissolution via Tandem IVRT-PSD Measurements

Figure 4. A) Dissolution profiles under high shear (syringe, solid red triangles) and low shear (micropipette, solid blue circles) at constant stirring rate; overlaid instantaneous dissolution rates (empty triangles and circles); B) Particle size D10 μ m, low shear (blue) and high shear (red); and **C)** percent light obscuration. Overlay of PSD measured simultaneously during dissolution **D**) low shear and E) high shear conditions; curves are color coded lightest to darkest from initial to final PSD (indicated by arrows) with one curve for each time point on the

The significance of these findings lies in the fact that there is a strong correlation between the (reversible) flocculation behavior of the particles (the cause), particle size distribution and dissolution rate results (the effects), which may impact not only the physical stability of the suspensions but also possible variations in clinical outcomes. Furthermore, measuring both PSD and dissolution behavior under varying shear conditions may be critical to the

WCS, JB, and YY acknowledge support of fellowships from the Oak Ridge Institute for Science and Education, administrated through an interagency agreement between the U.S. Department of Energy and

REFERENCES [1] Smith, W.C., *et al.* Int. J. Pharm. 604 (2021), DOI:10.1016/j.ijpharm.2021.120767